197 related articles for article (PubMed ID: 15939259)
1. Quest for effective agents to combat T-cell acute lymphoblastic leukemia.
Pui CH
Eur J Cancer; 2005 Jun; 41(9):1243-5. PubMed ID: 15939259
[No Abstract] [Full Text] [Related]
2. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
Kaspers GJ; Wijnands JJ; Hartmann R; Huismans L; Loonen AH; Stackelberg A; Henze G; Pieters R; Hählen K; Van Wering ER; Veerman AJ
Eur J Cancer; 2005 Jun; 41(9):1300-3. PubMed ID: 15869873
[TBL] [Abstract][Full Text] [Related]
3. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia.
Aricò M; Masera G
J Clin Oncol; 1997 Mar; 15(3):1285. PubMed ID: 9060574
[No Abstract] [Full Text] [Related]
4. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
5. Nelarabine.
Gandhi V; Keating MJ; Bate G; Kirkpatrick P
Nat Rev Drug Discov; 2006 Jan; 5(1):17-8. PubMed ID: 16485343
[No Abstract] [Full Text] [Related]
6. Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia?
Styczynski J; Wysocki M
J Clin Oncol; 2004 Mar; 22(5):963-4. PubMed ID: 14990658
[No Abstract] [Full Text] [Related]
7. Acute lymphoblastic leukemia in adolescents and young adults in Finland.
Usvasalo A; Räty R; Knuutila S; Vettenranta K; Harila-Saari A; Jantunen E; Kauppila M; Koistinen P; Parto K; Riikonen P; Salmi TT; Silvennoinen R; Elonen E; Saarinen-Pihkala UM
Haematologica; 2008 Aug; 93(8):1161-8. PubMed ID: 18556413
[TBL] [Abstract][Full Text] [Related]
8. Cellular drug sensitivity of immunophenotypic subgroups of childhood acute lymphoblastic leukemia.
Pieters R; Kaspers GJ; van Wering ER; Huismans DR; Loonen AH; Hählen K; Veerman AJ
Recent Results Cancer Res; 1993; 131():249-56. PubMed ID: 8210644
[No Abstract] [Full Text] [Related]
9. Building better therapy for children with acute lymphoblastic leukemia.
Carroll WL; Raetz EA
Cancer Cell; 2005 Apr; 7(4):289-91. PubMed ID: 15837616
[TBL] [Abstract][Full Text] [Related]
10. [Acute lymphoblastic leukemia, type T: therapeutic results].
Melero C; López J; García-Muñoz F; Auray C; García MJ; Gil C; Valverde F; Aracil J; Bernacer M; Contra T
An Esp Pediatr; 1988 Oct; 29 Suppl 34():62-6. PubMed ID: 3214040
[No Abstract] [Full Text] [Related]
11. Circumvention of glucocorticoid resistance in childhood leukemia.
Haarman EG; Kaspers GJ; Pieters R; Rottier MM; Veerman AJ
Leuk Res; 2008 Sep; 32(9):1417-23. PubMed ID: 18395253
[TBL] [Abstract][Full Text] [Related]
12. Have chemosensitizing strategies for multidrug-resistant childhood acute lymphoblastic leukemia come of age?
Bourquin JP; Bornhauser B
Expert Rev Hematol; 2010 Aug; 3(4):369-72. PubMed ID: 21083025
[No Abstract] [Full Text] [Related]
13. St Jude researchers use DNA chips to determine how leukemia cells responds to different drug treatments.
Pharmacogenomics; 2003 May; 4(3):244. PubMed ID: 12774778
[No Abstract] [Full Text] [Related]
14. [Clinical relevance of resistance against cytostatic agents in children with leukemia].
Pieters R; Kaspers GJ; Klumper E; van Wering ER; van der Does-van den Berg A; Veerman AJ
Ned Tijdschr Geneeskd; 1994 Apr; 138(14):706-12. PubMed ID: 8152511
[No Abstract] [Full Text] [Related]
15. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
16. Hyperglycemia during induction of acute lymphocytic leukemia.
Wilmott RW
J Pediatr; 2009 Jul; 155(1):A2. PubMed ID: 19559280
[No Abstract] [Full Text] [Related]
17. Pediatric regimens for adult acute lymphoblastic leukemia.
Stock W
Clin Adv Hematol Oncol; 2009 Apr; 7(4):244-6. PubMed ID: 19521325
[No Abstract] [Full Text] [Related]
18. [Drug sensitivity of tumor cells in varieties of acute childhood leukemia].
Shman TV; Belevtsev MV; Buglova SE
Vopr Onkol; 2005; 51(5):558-62. PubMed ID: 16756010
[TBL] [Abstract][Full Text] [Related]
19. [High-risk acute lymphoblastic leukemia].
Martínez Rubio A; Doñoro Mazario M; Sánchez Luna M; Muro Brussi M; Lamamie de Cleirac P; García-Monge Santidrián S
An Esp Pediatr; 1988 Oct; 29 Suppl 34():66-8. PubMed ID: 3214041
[No Abstract] [Full Text] [Related]
20. Ex vivo modulation of response to prednisolone in childhood acute lymphoblastic leukaemia.
Styczynski J; Wysocki M
Br J Haematol; 2006 May; 133(4):397-9. PubMed ID: 16643446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
